Michael DURUISSEAUX, Dr
Hospices Civils de Lyon - Hôpital Louis Pradel
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Michael DURUISSEAUX, Dr as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:14 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05200481 · Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)Intergroupe Francophone de Cancerologie Thoracique · active not recruiting · Non Small Cell Lung Cancer, ALK Gene Mutation · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:14 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 110 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Louisiana Manufactured Foods Regulatory Program StandardsU18FD006423 · FDA · LOUISIANA STATE OFFICE OF PUBLIC HEALTH · fiscal years 2022 · $224,952 awarded in 2022Same name and institution; not confirmed by an ID
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.